Chest
Authors: Go AS, Reynolds K, Tabada GH, Prasad PA, Sung SH, Garcia E, Portugal C, Fan D, Pai AP, Fang MC
Authors: Bero L, Lawrence R, Leslie L, Chiu K, McDonald S, Page MJ, Grundy Q, Parker L, Boughton S, Kirkham JJ, Featherstone R
Public health nutrition
Authors: Nagata JM, Ganson KT, Cattle CJ, Whittle HJ, Tsai AC, Weiser SD
AIDS (London, England)
Authors: DeJong C, Spinelli MA, Okochi H, Gandhi M
Journal of the National Cancer Institute
Authors: Alagoz O, Lowry KP, Kurian AW, Mandelblatt JS, Ergun MA, Huang H, Lee SJ, Schechter CB, Tosteson ANA, Miglioretti DL, Trentham-Dietz A, Nyante SJ, Kerlikowske K, Sprague BL, Stout NK
Authors: Banday AR, Stanifer ML, Florez-Vargas O, Onabajo OO, Zahoor MA, Papenberg BW, Ring TJ, Lee CH, Andreakos E, Arons E, Barsh G, Biesecker LG, Boyle DL, Burnett-Hartman A, Carrington M, Chang E, Choe PG, Chrisholm RL, Dalgard C, Edberg J, Erdmann N, Feigelson HS, Firestein GS, Gehring AJ, Ho M, Holland S, Hutchinson AA, Im H, Ison MG, Kim HB, Kreitman RJ, Korf BR, Mirabello L, Pacheco JA, Peluso MJ, Rader DJ, Redden DT, Ritchie MD, Rosenbloom B, Sant Anna HP, Savage S, Siouti E, Triantafyllia V, Vargas JM, Verma A, Vij V, Wesemann DR, Yeager M, Yu X, Zhang Y, Boulant S, Chanock SJ, Feld JJ, Prokunina-Olsson L
Genomic regions have been associated with COVID-19 susceptibility and outcomes, including the chr12q24.13 locus encoding antiviral proteins OAS1-3. Here, we report genetic, functional, and clinical insights into genetic associations within this locus. In Europeans, the risk of hospitalized vs. non-hospitalized COVID-19 was associated with a single 19Kb-haplotype comprised of 76 variants included in a 95% credible set within a large genomic fragment introgressed from Neandertals. The risk haplotype was also associated with impaired spontaneous but not treatment-induced SARS-CoV-2 clearance in a clinical trial with pegIFN-λ1. We demonstrate that two exonic variants, rs10774671 and rs1131454, affect splicing and nonsense-mediated decay of . We suggest that genetically-regulated loss of expression contributes to impaired spontaneous clearance of SARS-CoV-2 and elevated risk of hospitalization for COVID-19. Our results provide the rationale for further clinical studies using interferons to compensate for impaired spontaneous SARS-CoV-2 clearance, particularly in carriers of the risk haplotypes.
View on PubMed
Infection control and hospital epidemiology
Authors: Weber DJ, Al-Tawfiq JA, Babcock HM, Bryant K, Drees M, Elshaboury R, Essick K, Fakih M, Henderson DK, Javaid W, Juffras D, Jump RLP, Lee F, Malani AN, Mathew TA, Murthy RK, Nace D, O'Shea T, Pettigrew E, Pettis AM, Schaffzin JK, Shenoy ES, Vaishampayan J, Wiley Z, Wright SB, Yokoe D, Young H
